WO2010101627A3 - Methods and systems for treatment and/or diagnosis - Google Patents

Methods and systems for treatment and/or diagnosis Download PDF

Info

Publication number
WO2010101627A3
WO2010101627A3 PCT/US2010/000632 US2010000632W WO2010101627A3 WO 2010101627 A3 WO2010101627 A3 WO 2010101627A3 US 2010000632 W US2010000632 W US 2010000632W WO 2010101627 A3 WO2010101627 A3 WO 2010101627A3
Authority
WO
WIPO (PCT)
Prior art keywords
cascade
methods
systems
composition
biological
Prior art date
Application number
PCT/US2010/000632
Other languages
French (fr)
Other versions
WO2010101627A2 (en
Inventor
Geoffrey A. Von Maltzahn
Sangeeta N. Bhatia
Original Assignee
Massachusetts Institute Of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute Of Technology filed Critical Massachusetts Institute Of Technology
Priority to EP10709094A priority Critical patent/EP2403539A2/en
Priority to CA2754217A priority patent/CA2754217A1/en
Publication of WO2010101627A2 publication Critical patent/WO2010101627A2/en
Publication of WO2010101627A3 publication Critical patent/WO2010101627A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Abstract

The invention relates to methods and systems that can be used for treatment and/or diagnosis. In one aspect, the present invention involves systems and methods for activating a biological cascade in a subject, and administering, to the subject, a composition or a component comprising an agent able to bind a product of a biological cascade or otherwise interact with the biological cascade. The biological cascade may be, for example, a coagulation cascade, a complement cascade, an inflammation cascade, or the like. In some cases, the concentration of a protein, the metabolic demand for a substrate, or the like may be increased as a result of activation of the biological cascade. As a specific non-limiting example, in one set of embodiments, the biological cascade may be a coagulation cascade and the composition administered to the subject may include a fibrin-binding peptide and an antitumor species. By activating the biological cascade, e.g., with an activation composition or by applying energy, coagulation may be induced in a tumor, which the antitumor species may associate with due to an increase in fibrin caused by the coagulation cascade. In addition, in certain aspects, the present invention involves systems and methods for changing tissue from a first state to a second state, for instance, with a first composition comprising nanoparticles. The second composition may be more responsive to the tissue in the second state than in the first state in some cases. In still other aspects, the present invention is generally directed to systems and methods for making such compositions, systems and methods for promoting such compositions, kits involving such compositions, or the like.
PCT/US2010/000632 2009-03-02 2010-03-02 Methods and systems for treatment and/or diagnosis WO2010101627A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP10709094A EP2403539A2 (en) 2009-03-02 2010-03-02 Methods and systems for treatment and/or diagnosis
CA2754217A CA2754217A1 (en) 2009-03-02 2010-03-02 Methods and systems for treatment and/or diagnosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15667609P 2009-03-02 2009-03-02
US61/156,676 2009-03-02

Publications (2)

Publication Number Publication Date
WO2010101627A2 WO2010101627A2 (en) 2010-09-10
WO2010101627A3 true WO2010101627A3 (en) 2010-11-18

Family

ID=42224526

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/000632 WO2010101627A2 (en) 2009-03-02 2010-03-02 Methods and systems for treatment and/or diagnosis

Country Status (4)

Country Link
US (1) US20100260677A1 (en)
EP (1) EP2403539A2 (en)
CA (1) CA2754217A1 (en)
WO (1) WO2010101627A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8405379B1 (en) 2008-09-18 2013-03-26 Luc Montagnier System and method for the analysis of DNA sequences in biological fluids
US8593141B1 (en) 2009-11-24 2013-11-26 Hypres, Inc. Magnetic resonance system and method employing a digital squid
US8970217B1 (en) 2010-04-14 2015-03-03 Hypres, Inc. System and method for noise reduction in magnetic resonance imaging
US20120190049A1 (en) * 2010-12-10 2012-07-26 University Of Washington Through Its Center For Commercialization Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles
US11135174B2 (en) * 2011-04-13 2021-10-05 The Trustees Of The University Of Pennsylvania Coated mesoporous nanoparticles
EP3777896A1 (en) * 2012-03-15 2021-02-17 Immix Corporation Micelle comprising an inhibitor of nf-kb
US10441769B2 (en) * 2012-05-04 2019-10-15 University Of Houston Targeted delivery of active agents using thermally stimulated large increase of perfusion by high intensity focused ultrasound
WO2013169353A1 (en) * 2012-05-11 2013-11-14 University Of Iowa Research Foundation Multimodal imaging methods using mesoporous silica nanoparticles
CA2889583A1 (en) * 2012-10-25 2014-05-01 The Children's Hospital Of Philadelphia Affinity peptide-modified particles and targeted drug delivery methods
CA2894846A1 (en) * 2012-12-12 2014-06-19 Temple University - Of The Commonwealth System Of Higher Education Compositions and methods for treatment of cancer
WO2014149196A1 (en) * 2013-03-22 2014-09-25 University Of Florida Research Foundation, Inc. Polymer nanocomposites for early diagnosis of diseases
EP3415489A1 (en) 2013-10-18 2018-12-19 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2016065282A1 (en) * 2014-10-24 2016-04-28 The Regents Of The University Of Michigan Nasal formulation, nasal kit, and method for enhancing nasal nitric oxide (no) levels
US20210020264A1 (en) * 2018-03-20 2021-01-21 Cytomx Therapeutics, Inc. Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjects
CA3109223A1 (en) * 2018-08-16 2020-02-20 Beyondspring Pharmaceuticals, Inc. Method and composition for stimulating immune response
CN113786514A (en) * 2021-09-29 2021-12-14 复旦大学 Hemostatic composite material and preparation method thereof
CN114280202B (en) * 2022-01-04 2023-08-11 中国人民解放军陆军军医大学 Biomarker for diagnosing cadmium poisoning and application thereof
CN114652846B (en) * 2022-03-17 2024-01-09 天津工业大学 Enzyme-sensitive, tumor active targeting and intracellular quick drug release polymer prodrug, and preparation method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003026481A2 (en) * 2001-09-26 2003-04-03 Rice University Optically-absorbing nanoparticles for enhanced tissue repair
US20080213377A1 (en) * 2006-12-08 2008-09-04 Bhatia Sangeeta N Delivery of Nanoparticles and/or Agents to Cells
US20080248001A1 (en) * 2007-04-08 2008-10-09 Immunolight Methods and systems for treating cell proliferation disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5236410A (en) * 1990-08-02 1993-08-17 Ferrotherm International, Inc. Tumor treatment method
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
WO2000057951A1 (en) * 1999-03-26 2000-10-05 Flock Stephen T Delivery of pharmaceutical compounds and collection of biomolecules using electromagnetic energy and uses thereof
WO2008103369A2 (en) * 2007-02-19 2008-08-28 The Board Of Regents Of The University Of Oklahoma Composition and method for cancer treatment using targeted carbon nanotubes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003026481A2 (en) * 2001-09-26 2003-04-03 Rice University Optically-absorbing nanoparticles for enhanced tissue repair
US20080213377A1 (en) * 2006-12-08 2008-09-04 Bhatia Sangeeta N Delivery of Nanoparticles and/or Agents to Cells
US20080248001A1 (en) * 2007-04-08 2008-10-09 Immunolight Methods and systems for treating cell proliferation disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EL-SAYED ET AL: "Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles", CANCER LETTERS, NEW YORK, NY, US LNKD- DOI:10.1016/J.CANLET.2005.07.035, vol. 239, no. 1, 28 July 2006 (2006-07-28), pages 129 - 135, XP005525665, ISSN: 0304-3835 *
LOO C ET AL: "Immunotargeted nanoshells for integrated cancer imaging and therapy", NANO LETTERS APRIL 2005 AMERICAN CHEMICAL SOCIETY US, vol. 5, no. 4, April 2005 (2005-04-01), pages 709 - 711, XP002592045, DOI: DOI:10.1021/NL050127S *
NIIDOME ET AL: "PEG-modified gold nanorods with a stealth character for in vivo applications", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL LNKD- DOI:10.1016/J.JCONREL.2006.06.017, vol. 114, no. 3, 12 September 2006 (2006-09-12), pages 343 - 347, XP005634642, ISSN: 0168-3659 *
SIMBERG D ET AL: "Biomimetic amplification of nanoparticle homing to tumors", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA USA, vol. 104, no. 3, 16 January 2007 (2007-01-16), pages 932 - 936, XP002592046, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
US20100260677A1 (en) 2010-10-14
WO2010101627A2 (en) 2010-09-10
EP2403539A2 (en) 2012-01-11
CA2754217A1 (en) 2010-09-10

Similar Documents

Publication Publication Date Title
WO2010101627A3 (en) Methods and systems for treatment and/or diagnosis
WO2010087964A3 (en) Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof
UA101155C2 (en) Modified polypeptide of factor vii (fvii) and its using
WO2010017196A3 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
CA2863681A1 (en) Topical use of a skin-commensal prebiotic agent and compositions containing the same
MX2013011835A (en) Nutritional compositions including branched chain fatty acids for wound healing.
PH12018500641A1 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2008028946A3 (en) Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
WO2011060206A3 (en) Material and methods for treating or preventing her-3 associated diseases
WO2007141278A3 (en) Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof
BR112014009790A2 (en) compound for antisense modulation of gccr expression, its use and composition
TR201820051T4 (en) Use of Anti-factor XI Antibodies for Prevention or Treatment of Thrombus Formation
WO2010074588A3 (en) Pharmaceutical compounds
WO2010130830A3 (en) Anti-sclerostin vhh and their use for treating bone diseases
WO2012170807A3 (en) Anti-pseudomonas psl binding molecules and uses thereof
WO2009130616A3 (en) Improved tlr3 agonist compositions
EP4279128A3 (en) Novel antibody binding to tfpi and composition comprising the same
BRPI0920259A8 (en) MODIFIED BLOOD FACTOR MOLECULE, PHARMACEUTICAL COMPOSITION, AND, METHODS FOR PREPARING A MODIFIED BLOOD FACTOR MOLECULE AND FOR TREATING AN INDIVIDUAL SUFFERING FROM A BLOOD COAGULATION DISORDER
UA104712C2 (en) Method of treatment of bananas
WO2011116026A3 (en) Inhibitors of beta integrin-g protein alpha subunit binding interactions
WO2009062576A8 (en) Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same
WO2014140103A3 (en) Thrombin sensitive coagulation factor x molecules
WO2007100765A3 (en) Lysozyme-modified probiotic components and uses thereof
BRPI1013956B8 (en) method for isolating a recombinant protein, spray dried particles, composition, and use of spray dried particles
WO2010100570A3 (en) Activated leukocyte composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10709094

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2754217

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010709094

Country of ref document: EP